Philadelphia University + Thomas Jefferson University
News & Events

<< Back to News & Events List

One Size Doesn’t Fit All: Patients with Metastatic Cancer May Need Stronger Anti-Coagulation Therapy Following Bone Lesion Surgery

09/21/15

(PHILADELPHIA) –Jefferson researchers identified a high risk for venous thromboembolism (VTE), or blood clots, following surgery for long-bone reconstruction in patients with metastatic cancer. They published the results in the Journal of Bone and Joint Surgery.

“Our study shows not only that a stronger anti-coagulation therapy may be warranted for these patients, but also that each case needs individualized attention,” said senior author John A. Abraham, M.D., Associate Professor of Orthopedic Surgery and Radiation Oncology in the Sidney Kimmel Medical College at Thomas Jefferson University, Director of the Jefferson Sarcoma and Bone Tumor Center, and orthopedic surgeon specializing in orthopedic oncology at Rothman Institute at Jefferson.

The team retrospectively reviewed 336 cases where patients required intramedullary nailing for metastatic bone lesions, during which a surgeon places a metal rod into the bone to provide support. The study revealed that 24 patients (7.1 percent) developed thromboembolism in the 90 days after surgery and found a low incidence of post-operative wound complications (3.1 percent), suggesting a different anti-coagulation protocol may be tolerated.

“Venous thromboembolism, including pulmonary embolism and symptomatic deep vein thrombosis, can have devastating consequences for patients,” said co-author Geno J. Merli, M.D., Professor of Medicine and Surgery in the Sidney Kimmel Medical College at Thomas Jefferson University; Co-Director of Jefferson Vascular Center; and expert in anticoagulation therapy. “Our findings underscore the importance of evaluating each patient for risk factors to select the most appropriate and effective anticoagulation therapy. In addition, patients with metastatic cancer may require extended prophylaxis to prevent deep vein thrombosis and pulmonary embolism.”

“We also found that 66 percent of the patients who developed blood clots 90 days after surgery also had a primary cancer of the lung,” Dr. Abraham said. “This suggests the risk for venous thromboembolism is different depending on the primary cancer. This will require a change in our way of thinking as orthopedic surgeons.”

Dr. Abraham’s research revealed that patients who did not receive radiation therapy after surgery had a slightly decreased risk of developing a blood clot, which approached statistical significance.  

“The implications of this study are quite broad. It demonstrates that skeletal metastatic disease is not just one simple entity, but rather a complex process that has specific effects associated with each individual primary disease,” said Atrayee Basu-Mallick, M.D., Clinical Assistant Professor in the Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University, who was not involved in the study. “It also highlights the importance of having a team approach to skeletal metastases, which includes the oncologic, medical, radiation, and surgical teams. It should change the way most cancer centers approach skeletal metastases.”

Dr. Basu-Mallick, who is also the Medical Program Director of the Center for Sarcoma and Bone Tumor Oncology at Jefferson, pointed out that more studies are needed to prove that a longer duration of anticoagulation is needed for patients with skeletal metastases after surgery to help reduce rates of thromboembolic events in this vulnerable population.

In light of these findings, Dr. Abraham and his team recommend physicians consider a patient’s primary cancer while selecting the anti-coagulation therapy following surgery for intramedullary nailing and close coordination with the patient’s medical oncology team.

Reference: Shallop, B., et al. Thromboembolism After Intramedullary Nailing for Metastatic Bone Lesions. J Bone Joint Surg Am, 2015 Sep 16; 97 (18): 1503 -1511. http://dx.doi.org/10.2106/JBJS.N.01067

###

About Jefferson — Health is all we do.

Our newly formed organization, Jefferson, encompasses Thomas Jefferson University and Jefferson Health, representing our academic and clinical entities.  Together, the people of Jefferson, 19,000 strong, provide the highest-quality, compassionate clinical care for patients, educate the health professionals of tomorrow, and discover new treatments and therapies that will define the future of health care.

Jefferson Health comprises five hospitals, 13 outpatient and urgent care centers, as well as physician practices and everywhere we deliver care throughout the city and suburbs across Philadelphia, Montgomery and Bucks Counties in Pa., and Camden County in New Jersey.  Together, these facilities serve more than 78,000 inpatients, 238,000 emergency patients and 1.7 million outpatient visits annually.  Thomas Jefferson University Hospital is the largest freestanding academic medical center in Philadelphia.  Abington Hospital is the largest community teaching hospital in Montgomery or Bucks counties.  Other hospitals include Jefferson Hospital for Neuroscience in Center City Philadelphia; Methodist Hospital in South Philadelphia; and Abington-Lansdale Hospital in Hatfield Township. 

Thomas Jefferson University enrolls more than 3,900 future physicians, scientists, nurses and healthcare professionals in the Sidney Kimmel Medical College (SKMC), Jefferson Colleges of Biomedical Sciences, Health Professions, Nursing, Pharmacy, Population Health and is home of the National Cancer Institute (NCI)-designated Sidney Kimmel Cancer Center.

For more information and a complete listing of Jefferson services and locations, visit www.jefferson.edu.

Contact: Gail Benner
Public Affairs Specialist
Gail.Benner@Jefferson.edu 
Office: 215-955-2240
Cell: 267-283-8382